VANCOUVER, British Columbia, Sept. 27, 2022 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, is pleased to announce filing of a PCT patent application along with a U.S. application for lysergic acid…


Previous articleatai Life Sciences Announces Initiation of Phase 1 Trial for its MDMA Derivative, EMP-01
Next articleMindMed Announces Proposed Public Offering of Common Shares